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ABSTRACT: 
Background & Aims: Fecal microbiota transplantation (FMT) is effective for treating 
recurrent Clostridioides difficile infection (CDI), but there are concerns about its long-term 
safety. Understanding the mechanisms of the effects of FMT could help us design safer, 
targeted therapies. We aimed to identify microbial metabolites that are important for C 
difficile growth. 
 
Methods: We used a CDI chemostat model as a tool to study the effects of FMT in vitro. The 
following analyses were performed: C difficile plate counts, 16S rRNA gene sequencing, 1H-
NMR spectroscopy, and UPLC mass spectrometry bile acid profiling. FMT mixtures were 
prepared using fresh fecal samples provided by donors enrolled in an FMT program in the 
United Kingdom. Results from chemostat experiments were validated using human stool 
samples, C difficile batch cultures, and C57BL/6 mice with CDI. Human stool samples were 
collected from 16 patients with recurrent CDI and healthy donors (n=5) participating in an 
FMT trial in Canada.  
 
Results: In the CDI chemostat model, clindamycin decreased valerate and deoxycholic acid 
concentrations and increased C difficile total viable counts (TVC) and valerate precursors, 
taurocholic acid, and succinate concentrations. After we stopped adding clindamycin, levels 
of bile acids and succinate recovered, whereas levels of valerate and valerate precursors did 
not. In the CDI chemostat model, FMT increased valerate concentrations and decreased C 
difficile TVC (94% reduction), spore counts (86% reduction), and valerate precursor 
concentrations—concentrations of bile acids were unchanged. In stool samples from patients 
with CDI, valerate was depleted before FMT, but restored after FMT. C difficile batch 
cultures confirmed that valerate decreased vegetative growth, and that taurocholic acid is 
required for germination but had no effect on vegetative growth. C difficile TVC were 
decreased by 95% in mice with CDI given glycerol trivalerate compared to phosphate-
buffered saline. 
 
Conclusions: We identified valerate as a metabolite that is depleted with clindamycin and 
only recovered with FMT. Valerate is a target for a rationally designed recurrent CDI 
therapy. 
 
Key words:  bacteria; stool transplant; gut microbiome; pathogen 
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INTRODUCTION: 
Clostridioides difficile (formerly Clostridium difficile) is an anaerobic, spore-forming, Gram-
positive bacterium that causes opportunistic infections in the human colon, usually after antibiotic 
exposure. C difficile infection (CDI) can lead to diarrhoea, pseudomembranous colitis, toxic 
megacolon, intestinal perforation, multi-organ failure, and death.
1
 A recent study showed that the 
incidence of recurrent CDI has disproportionately increased relative to CDI overall, therefore the 
demand for recurrent CDI therapies may be rising.
2
 
The principle behind faecal microbiota transplantation (FMT) is to use stool from a healthy donor 
to replace the microorganisms and ecosystem functions that are depleted in the gut of recurrent CDI 
patients. While FMT is highly effective at treating recurrent CDI,
3
 it lacks a detailed mechanism of 
action and it is unclear whether all the microbes included in the preparations are required to resolve 
disease. There are concerns regarding the long-term safety, reproducibility, composition, and 
stability of FMT preparations,
4
 and potential risks include transmission of infections, invasive 
administration routes, and concerns treating high-risk individuals (frail/elderly or 
immunosuppressed patients). In addition, as more studies describe the role of the gut microbiota in 
disease, it is unclear whether FMT could result in the transfer of a gut microbiota which later 
contributes to disease (e.g. colorectal cancer, obesity, inflammatory bowel disease, etc). 
C difficile causes disease after germination, where cells change from their dormant spore state to 
their active vegetative state.
5
 Previous studies have suggested that exposure to antibiotics alters the 
composition and functionality of the gut microbiota, changing the global metabolic profile to an 
environment that supports C difficile germination and vegetative growth.
6
 Studies have shown that 
antibiotic exposure and FMT alters many microbial metabolic pathways, including bile acid 
metabolism
7
 and succinate metabolism.
8
 In fact, Ott and colleagues showed that sterile faecal 
filtrate from healthy stool donors was able to cause remission from recurrent CDI in a preliminary 
investigation of five patients with the condition.
9
 It is possible the sterile faecal filtrate contained 
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bacterial metabolites or enzymes that were sufficient to inhibit C difficile spore germination and 
vegetative growth. 
Mechanistic studies are challenging to conduct in vivo due to the wide variety of factors which 
influence the composition and functionality of the gut microbiota. Firstly, samples from recurrent 
CDI patients prior to FMT are usually collected while they are still on suppressive vancomycin. 
Therefore, it is difficult to determine whether changes in specific bacteria or metabolites following 
FMT are due to the FMT administration, or whether these changes could have occurred in the 
absence of FMT due to recovery of the gut microbiota following cessation of antibiotic treatment. 
Changes in diet can also cause profound changes in the composition and functionality of the gut 
microbiota, especially short chain fatty acid production,
10
 and diet is especially difficult to control in 
human studies. Recurrent CDI patients may eat differently before and after receiving FMT, and may 
eat differently from healthy controls. Studies on diet, the gut microbiota, and short chain fatty acid 
production have often relied on fermentation data in vitro and animal data due to the challenges 
associated with human studies.
11
 Therefore, human studies could lead to “false positives” for 
mechanisms of C difficile pathogenesis. 
Data collected from chemostat studies can be used to complement microbiome data collected 
from human and animal studies to more easily determine a mechanism of action for specific disease 
states or interventions.
12
 Chemostat models are artificial systems that mimic some of the spatial, 
temporal, and environmental conditions found in the human gut.
13
 Chemostats have many 
advantages over human and animal studies, which have been discussed in detail previously.
12
 
Bacterial communities cultured in these models are highly reproducible, stable, complex, and 
representative of the bacterial communities found in vivo.
14,15
 This means researchers can perform 
longitudinal studies in these systems that can directly link changes in the gut microbiota structure 
and function to an experimental intervention. Chemostats have previously been used to model CDI 
and test the effects of several treatments on C difficile growth and pathogenesis (e.g. antibiotics,
16-19
 
bacteriophages,
20
 and lactoferrin
21
). 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 
 
We used a twin-vessel single-stage distal gut chemostat model as a tool to study CDI and the 
effects of FMT under tightly-controlled conditions in vitro. We hypothesised that exposure to 
antibiotics kills bacteria that perform important functions in the gut microbial ecosystem, resulting 
in a “metabolic dysbiosis” where the loss or reduction of specific microbial metabolic pathways 
creates an environment that promotes C difficile germination and growth. We also hypothesised 
that FMT administration would reverse these effects by restoring the bacteria responsible for 
performing these key metabolic functions. Our aim was to identify these metabolites so we could 
propose new therapeutic approaches to treat recurrent CDI that are well-defined, effective, and 
safe.  
 
MATERIALS AND METHODS: 
Chemostat model of CDI: 
The chemostat models used in this study were two identical Electrolab FerMac 200 series 
bioreactor systems (Electrolab, Tewkesbury, UK). Chemostat inoculum and growth medium were 
prepared and vessels were inoculated and operated as previously described (see Supplementary 
Methods).
14
 Stool samples were collected under approval from the UK National Research Ethics 
Centres (13/LO/1867). We performed three separate twin-vessel chemostat experiments. In each 
experiment, two identical vessels (“VA” receiving saline vehicle control and “VB” receiving FMT 
preparation) were inoculated with a 10% (w/v) faecal slurry prepared using fresh faeces from a 
healthy donor not exposed to antibiotics within the previous 2 months (Run 1= male in his 40's; Run 
2= male in his 60’s; Run 3= male in his 80’s). We used clindamycin and C difficile spores to induce CDI 
in our chemostat model following a modified version of the methods previously described by 
Freeman and colleagues (see Table 1 and Supplementary Methods).
22
 After stopping clindamycin 
dosing, microbial communities were allowed to stabilise before administering the FMT preparation 
or saline vehicle control. FMT mixtures were prepared using fresh faecal samples provided by donors 
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enrolled within Imperial’s FMT Programme.
23
 Stool samples from these faecal donors have 
previously been used to successfully treat recurrent CDI patients.  
 
16S rRNA gene sequencing (metataxonomics): 
DNA extraction is described in the Supplementary Methods. Sample libraries amplifying the V3-
V4 region of the 16S rRNA gene were prepared following Illumina’s 16S Metagenomic Sequencing 
Library Preparation Protocol,
24
 with a few modifications. First, we used the SequalPrep 
Normalization Plate Kit (Life Technologies, Carlsbad, USA) to clean up and normalise the index PCR 
reactions. Also, we used the NEBNext Library Quant Kit for Illumina (New England Biolabs, Ipswich, 
USA) to quantify the sample libraries. Sequencing was performed on an Illumina MiSeq platform 
(Illumina Inc, San Diego, USA) using the MiSeq Reagent Kit v3 (Illumina) and paired-end 300 bp 
chemistry. The resulting data were pre-processed and analysed as described in the Supplementary 
Methods. 
 
1
H-NMR spectroscopy: 
Chemostat culture supernatants were prepared for 
1
H-NMR as described in the Supplementary 
Methods. One-dimensional 
1
H-NMR spectra were acquired from chemostat culture supernatants at 
300 K on a Bruker DRX 600 MHz NMR spectrometer or a Bruker AVANCE III 600 MHz NMR 
spectrometer (Bruker Biospin, Germany). A standard one-dimensional NMR pulse sequence [RD-90°-
t1-90°-tm-90°-acq] was used with a recycle delay (4 s) and mixing time (100 ms). The 90° pulse length 
was around 10 μs and 32 scans were recorded. Metabolites concentrations were quantified from 
spectra using the Chenomx NMR suite software (Chenomx Inc, Edmonton, Canada).
25
 
To confirm the identity of key metabolites in chemostat culture supernatants a series of NMR 
spectra including 1D 
1
H NOESY, 2D 
1
H−
1
H TOCSY and 
1
H−
1
H COSY of a chemostat culture supernatant 
and a metabolite standard were recorded (see Supplementary Methods). 
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Ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) bile acid profiling: 
Bile acids were extracted from 50 µL of chemostat culture by adding 150 µL of cold methanol, 
followed by incubation at -30ᵒC for 2 hours. Tubes were centrifuged at 9500 x g and 4ᵒC for 20 min 
and 120µL of supernatant was loaded into vials. Bile acid analysis was performed using an ACQUITY 
UPLC (Waters Ltd, Elstree, UK) coupled to a Xevo G2 Q-ToF mass spectrometer. The MS system was 
equipped with an electrospray ionization source operating in negative ion mode, using methods 
previously described by Sarafian and colleagues.
26
 Data pre-processing and analysis are described in 
the Supplementary Methods. 
 
Gas chromatography-mass spectrometry (GC-MS) analysis of human stool samples: 
Human stool samples were collected from recurrent CDI patients (n=16) and healthy donors (n=5) 
as part of a randomised clinical trial comparing the efficacy of capsulized and colonoscopic FMT for 
the treatment of recurrent CDI, as previously described.
27
  Pre-FMT samples were collected from 
recurrent CDI patients while on suppressive vancomycin. Post-FMT samples were collected 1, 4, and 
12 weeks after FMT treatment. All patients were successfully treated following a single FMT.  
A targeted GC-MS protocol was used to identify and quantify short chain fatty acids from human 
stool samples as previously-described.
28
  Samples were analysed on an Agilent 7890B GC system, 
coupled to an Agilent 5977A mass selective detector (Agilent, Santa Clara, CA).  Data analysis was 
performed using MassHunter software (Agilent). 
 
C difficile batch cultures: 
We tested the effects of valerate (Fisher Scientific) on the vegetative growth of three C difficile 
ribotypes (010, 012, and 027) as well as several gut commensal bacteria (Bacteroides uniformis, 
Bacteroides vulgatus, and Clostridium scindens) (see Supplementary Methods). We centrifuged an 
overnight culture of the test isolate at 3000 x g for 10 minutes and resuspended the cells in brain 
heart infusion broth (Sigma-Aldrich) (supplemented with 5 mg/mL yeast extract (Sigma-Aldrich), and 
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0.1% L-cysteine (Sigma-Aldrich)), containing varying concentrations of valerate (0, 1, 2, 3, 4, 5, 10, 
and 20 mM, pH of broth adjusted to 6.8) in triplicate. The OD600 was measured at time zero and 
cultures were incubated at 37ᵒC in an ElectroTek AW 400TG Anaerobic Workstation (ElectroTek, 
West Yorkshire, UK). Additional OD600 measurements were taken at 2, 4, 6, and 8 hours post-
inoculation. We plotted the changes in OD600 (from a time point during the exponential phase) 
against each concentration of valerate tested. We used ANOVA and Tukey post hoc test to 
determine whether the concentration of valerate tested affected the growth of the test isolate 
compared to batch cultures grown in the absence of valerate. 
We also tested the effects of taurocholic acid (TCA) on C difficile germination and vegetative 
growth using batch cultures (see Supplementary Methods). 
 
Mouse model of CDI: 
Mouse experiments were performed under the authority of the UK Home Office outlined in the 
Animals (Scientific Procedures) Act 1986 after ethical review by Imperial College London Animal 
Welfare and Ethical Review Body (PPL 70/7969). We adhered to standards articulated in the Animal 
Research: Reporting of In Vivo Experiments (ARRIVE) guidelines. 
Wild-type C57BL/6 mice (8-10-week-old; female) were purchased from Envigo (UK) and 
acclimatised for 1 week prior to use. Mice were housed five per cage in individually ventilated cages 
with autoclaved food (RM1, Special Diet Services), bedding (Aspen chip 2 bedding), and water 
(provided ad libitum). Mice were subjected to a 12 h light and 12 h dark cycle at 20–22°C.  
We used a previously published mouse model of C difficile infection as described by Winston and 
colleagues (Figure 6A).
29
 Briefly, mice were given 0.5 mg/ml cefoperazone in their drinking water for 
5 days (from day -7 to day -2), followed by autoclaved antibiotic-free water for the remainder of the 
experiment. C difficile spores were prepared and enumerated (see Supplementary Methods) and 
mice were challenged with 10
5
 C difficile spores by oral gavage on day 0. Mice were orally gavaged 
with 200 µl of 15 mM glycerol trivalerate (n=5) or 200 µl of PBS (n=5) on days 1, 2, and 3. Faecal 
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samples were collected on days 1, 2, 3, and 4 and C difficile total viable counts (TVC) were quantified 
(see Supplementary Methods). Mice were not fasted before oral gavages and all interventions were 
performed during the light cycle. 
 
Statistical analysis and data integration: 
Statistical tests were performed using IBM SPSS Statistics Software version 23 (paired t-test, 
independent t-test, ANOVA) or GraphPad Prism version 7.03 (Mann-Whitney U test, Friedman test). 
Short AsyNchronous Time-series Analysis (SANTA) was used to determine whether there were 
significant changes in data trajectories at several time periods over the course of the chemostat 
experiments (see Supplementary Methods).
30
 Spearman's rho statistic and p-values were calculated 
for C difficile TVC and metabolite data using the cor and cor.test functions, respectively, within the 
stats base library within R. A p-value less than 0.05 was considered significant. We used regularised 
Canonical Correlation Analysis (rCCA) to correlate metataxonomic and metabolomic data using the 
mixOmics library within R (see Supplementary Methods).
31
 
 
RESULTS: 
C difficile total viable counts and spore counts from chemostat culture samples: 
Following the addition of C difficile spores to each vessel C difficile TVC and spore counts were 
enumerated every other day until the end of the experiment (Figure 1). We found an increase in C 
difficile TVC during the clindamycin-dosing period (p<0.001). We also found a 94% reduction in C 
difficile TVC (p=0.025) and an 86% reduction in C difficile spore counts (p=0.034) in FMT-treated 
cultures compared to saline-treated cultures. 
 
Bacterial community composition of chemostat culture samples: 
We found that clindamycin dosing of chemostat cultures altered the composition and the 
biomass of the bacterial communities (Figure S1). Clindamycin dosing caused an initial decrease in 
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the total bacterial biomass one day after starting clindamycin dosing (p<0.001), however the total 
bacterial biomass increased over time to reach pre-clindamycin levels by the end of the clindamycin 
dosing period (p>0.05). Clindamycin dosing also resulted in a decrease in bacterial diversity 
(p=0.002), richness (the number of species present, p=0.001) and evenness (how evenly distributed 
each species is, p=0.004) (Figure S2). There was a significant increase in richness following FMT 
treatment (p=0.035), however diversity (p>0.05) and evenness (p>0.05) remained unchanged. 
 
Global metabolic profiling of chemostat culture samples by 
1
H-NMR spectroscopy: 
We performed 
1
H-NMR spectroscopy as an exploratory technique to generate global metabolite 
spectral profiles for samples collected over the course of the chemostat experiments. There was a 
significant decrease in valerate (p=0.004), butyrate (p=0.004), and acetate (p=0.013) and a significant 
increase in 5-aminovalerate (p=0.004), ethanol (p=0.021), succinate (p=0.004), and isobutyrate 
(p=0.004) during the clindamycin dosing period compared to the steady state period (Figures 2 and 
S3). rCCA modelling was used to determine correlations between 16S rRNA gene sequencing data 
and metabolite data that correspond to clindamycin dosing. The unit representation plot showed a 
clear separation between steady state cultures and cultures sampled during and after the 
clindamycin dosing period (Figure S4A). The correlation circle plot showed that the separation 
between the cultures was due to decreases in the levels of valerate and acetate, and increases in the 
levels 5-aminovalerate, succinate, isobutyrate, and ethanol during and after the clindamycin dosing 
period (Figure S4B). This plot also showed strong correlations between bacterial genera and these 
metabolites. During the clindamycin-dosing period there were significant correlations between C 
difficile TVC and valerate (rS=-0.59, p=0.005), 5-aminovalerate (rS=0.54, p=0.010), and succinate (rS=-
0.49, p=0.022). 
Following the end of the clindamycin-dosing period the levels of succinate, butyrate, acetate, and 
isobutyrate recovered to pre-antibiotic levels, and these levels were not affected by FMT treatment 
(Figures 2 and S3). However, after stopping clindamycin dosing the levels of valerate (p=0.009) were 
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still significantly decreased and the levels of 5-aminovalerate (p=0.009) and ethanol (p=0.013) were 
still significantly increased compared to pre-antibiotic levels (Figure 2), indicating the levels of these 
metabolites did not recover after stopping clindamycin dosing. Moreover, after stopping clindamycin 
dosing the levels of isovalerate decreased (p=0.009) and the levels of propionate increased (p=0.036) 
compared to pre-antibiotic levels (Figures 2 and S3). 
There was a significant increase in valerate (p=0.032), and significant decreases in 5-
aminovalerate (p=0.032), ethanol (p=0.032), propionate (p=0.032), and methanol (p=0.039) in FMT-
treated cultures compared to saline-treated cultures (Figure 2). rCCA modelling was also used to 
determine correlations between 16S rRNA gene sequencing data and metabolite data that 
correspond to FMT or saline treatment. The unit representation plot showed a clear separation 
between FMT-treated cultures and saline-treated cultures along the second canonical variate (Figure 
S4C). The correlation circle plot showed that the separation between FMT- and saline-treated 
cultures was due to increases in the levels of valerate and decreases in the levels of 5-aminovalerate, 
ethanol, and methanol in FMT-treated cultures (Figure S4D). This plot also showed strong 
correlations between bacterial genera and these metabolites. Following FMT or saline treatment 
there was a significant strong negative correlation between C difficile TVC and valerate (rS=-0.67, 
p=1.48x10
-4
), and significant strong positive correlations between C difficile TVC and 5-aminovalerate 
(rS=0.76, p=6.07x10
-6
), ethanol (rS=0.81, p=1.72x10
-6
), and methanol (rS=0.72, p=2.98x10
-5
).  
The identity of the proposed valerate peaks was confirmed in the chemostat culture supernatants 
by performing 1D-
1
H-NMR spectroscopy of a sample before and after valerate spike-in, as well as 
2D-
1
H-NMR spectroscopy of a valerate-containing sample (Figures S5 and S6, Supplementary 
Results). The identities of other metabolites were also confirmed in the chemostat culture 
supernatants by performing 2D-
1
H-NMR and STOCSY (Figures S7 and S8). 
 
Bile acid UPLC-MS profiling of chemostat culture samples: 
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Due to the important role that bile acids play in C difficile spore germination and vegetative 
growth,
5
 we also measured changes in bile acids over the course of the chemostat experiments. 
During the clindamycin dosing period there was a significant increase in the conjugated primary bile 
acids taurocholic acid (TCA, p=0.004), glycocholic acid (GCA, p=0.005), and glycochenodeoxycholic 
acid (GCDCA, p=0.005), in the unconjugated primary bile acids cholic acid (CA, p=0.004) and 
chenodeoxycholic acid (CDCA, p=0.037), and in the conjugated secondary bile acids taurodeoxycholic 
acid (TDCA, p=0.045) and glycodeoxycholic acid (GDCA, p=0.004) (Figures 3 and S9). During the 
clindamycin dosing period there was a significant decrease in the secondary bile acids deoxycholic 
acid (DCA, p=0.006), lithocholic acid (LCA, p=0.005), and ursodeoxycholic acid (UDCA, p=0.037) 
(Figures 3 and S9). Following the end of the clindamycin dosing period the levels of these bile acids 
recovered to steady state levels (before clindamycin dosing), and these levels were not affected by 
FMT treatment. 
rCCA modelling was used to determine correlations between 16S rRNA gene sequencing data and 
bile acid data during the clindamycin-dosing period. The unit representation plot showed separation 
between cultures sampled before and during the clindamycin-dosing period along the first canonical 
variate, but no separation between cultures sampled before and after the clindamycin-dosing period 
(Figure S10A). The correlation circle plot showed that the separation between cultures sampled 
before and during clindamycin dosing was due to increases in the levels of TCA, CA, CDCA, GCA, 
GDCA, and GCDCA, and decreases in the levels of DCA, LCA, and UDCA during the clindamycin-dosing 
period (Figure S10B). This plot also showed strong correlations between bacterial genera and bile 
acids.  
There were significant strong correlations between C difficile TVC and several bile acids during 
the clindamycin dosing period, including TCA (rS=0.68, p=6.29x10
-4
), CA (rS=0.61, p=0.003), DCA (rS=-
0.75, p=8.86x10
-5
), and LCA (rS=-0.76, p=6.36x10
-5
). 
 
GC-MS analysis of human stool samples: 
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To confirm the findings from our chemostat experiments we measured the levels of valerate 
in human stool samples from healthy FMT donors, recurrent CDI patients pre-FMT and at several 
time points post-successful FMT (1, 4, and 12 weeks after FMT treatment) (Figure 4). Valerate was 
depleted in stool samples from recurrent CDI patients pre-FMT compared to healthy donors 
(p=0.0075).  Valerate levels were significantly increased in CDI patients post-FMT compared to pre-
FMT (p=0.0007 at 1 week, 4 weeks, and 12 weeks). There were no significant differences in the levels 
of valerate in stool samples from healthy donors compared to any of the time points from CDI 
patients collected post-FMT (p>0.05 for all comparisons). 
 
C difficile batch culture experiments with valerate and TCA: 
Batch culture experiments were performed to directly study the effects of specific metabolites of 
interest on C difficile germination and vegetative growth and to confirm the findings from our 
chemostat experiments. These experiments showed that valerate inhibited the vegetative growth C 
difficile ribotype 010 at concentrations ≥ 4 mM (p=0.008), ribotype 012 at concentrations ≥ 2 mM 
(p=0.003), and ribotype 027 at concentrations ≥ 2 mM (p=0.008) (Figure 5). The concentration of 
valerate in FMT-treated chemostat culture supernatants remained above 4 mM for all samples, 
whereas the concentration of valerate in saline-treated cultures remained below 2 mM for all 
samples. As a control, we also tested the effects of valerate on commensal gut isolates (B uniformis 
and B vulgatus, two representatives of Bacteroidetes, and C scindens, a representative of 
Firmicutes). B uniformis was only inhibited in broth containing 20 mM valerate (p=0.026). B vulgatus 
was not inhibited at any concentration of valerate that was tested, and showed more growth in 
broths containing 10 mM (p=0.020) or 20 mM (p=0.019) valerate. C scindens was not inhibited at any 
concentration of valerate tested (p>0.05 for all concentrations of valerate tested). 
Batch culture experiments also confirmed previous findings showing that TCA is required for C 
difficile spore germination but had no effect on vegetative growth (Figure S11). 
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Glycerol trivalerate intervention study in a CDI mouse model: 
Next, we determined whether valerate could inhibit C difficile growth when administered as an 
intervention in a CDI mouse model (Figure 6A). To avoid the rapid uptake of valerate and obtain 
sufficient release in the gastrointestinal tract, valerate was administered to the mice in the form of 
glycerol trivalerate (which is hydrolysed by lipases to release valerate
32
). One-day post-infection 
(prior to glycerol trivalerate or PBS administration) there was no significant difference in the levels of 
C difficile TVC in mouse faeces in each group (p=0.584).  Glycerol trivalerate or PBS was administered 
to C difficile-infected mice by oral gavage 1, 2, and 3 days post-infection (n=5 per group). There was 
a significant decrease in C difficile TVC in glycerol trivalerate-treated mice compared to PBS-treated 
mice (Figure 6B, p=0.027 on day 2, p=0.007 on day 3, and p=0.024 on day 4). After only 3 doses of 
glycerol trivalerate or PBS, glycerol trivalerate-treated mice had an average of 95% less C difficile TVC 
per gram of faeces compared to PBS-treated mice. No adverse effects were noted in glycerol 
trivalerate-treated mice over the course of the experiment. These results corroborate the other 
findings presented in this study and support the therapeutic use of valerate to treat CDI. 
 
DISCUSSION: 
We used several ‘omic’ techniques to study the effects of FMT on CDI in a chemostat model 
under tightly controlled conditions. The aim of our study was to directly link changes in C difficile 
counts to changes in the structure and function of the cultured faecal microbiota. We confirmed our 
findings by analysing human stool samples, performing C difficile batch culture experiments, and 
performing an interventional study in a CDI mouse model. A summary of the key findings and 
proposed interactions between C difficile, valerate, and TCA are outlined in Figure S12. 
In our study we found valerate significantly inhibited the growth of C difficile, both in vitro and in 
vivo. Valerate is a short chain fatty acid produced via amino acid fermentation by members of the 
gut microbiota.
33
 Valerate was significantly depleted in chemostat culture samples during 
clindamycin dosing and did not recover after clindamycin dosing was stopped. Valerate significantly 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
increased with FMT treatment and had a strong negative correlation with C difficile TVC. These 
findings were corroborated with human data which showed valerate was depleted in recurrent CDI 
patient stool but was restored following successful FMT. Batch culture experiments confirmed that 
valerate directly inhibited the vegetative growth of several C difficile ribotypes, but had minimal 
effects on the growth of other commensal gut bacteria tested. Moreover, we showed that glycerol 
trivalerate significantly decreased C difficile TVC in a CDI mouse model. We hypothesise that 
maintaining or restoring the levels of valerate in the gut microbiota of CDI patients will inhibit the 
vegetative growth of C difficile. This restoration could be accomplished by directly supplying the gut 
with valerate (e.g. in the form of glycerol trivalerate) or by administering bacteria capable of 
transforming valerate precursors into to valerate.  
There are several different metabolic pathways that lead to valerate production. 5-aminovalerate 
is a product of the anaerobic degradation of protein hydrolysates by members of the gut microbiota, 
in particular Clostridium species.
34
 In this pathway, proline is reduced to 5-aminovalerate by proline 
reductase in a Stickland-type fermentation.
35-37
 5-aminovalerate is then fermented to valerate in a 
series of reactions mediated by gut bacteria.
34,38
 We showed that 5-aminovalerate was increased in 
chemostat cultures following clindamycin dosing and remained increased after clindamycin dosing 
was stopped. This finding is supported by data from a patent submitted by Savidge and Dann, who 
proposed CDI patients can be distinguished from non-infected subjects by measuring elevated levels 
of 5-aminovalerate in the patient’s stool, urine, or blood.
39
 Moreover, Fletcher and colleagues 
showed that 5-aminovalerate was elevated in the caecal content of C difficile infected mice.
40
 In 
another metabolic pathway, some Clostridium species can ferment ethanol and propionate to 
valerate.
41
 We found ethanol and propionate increased after clindamycin dosing and decreased 
following FMT treatment. Taken together, changes in the levels of valerate and valerate precursors 
(5-aminovalerate, ethanol, and propionate) over the course of our chemostat experiments supports 
our hypothesis that disruption of the valerate pathway due to antibiotics results in an environment 
that permits C difficile vegetative growth. 
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In this study we performed an intervention experiment to test the effects of valerate (in the form 
of glycerol trivalerate) in a CDI mouse model. For the first time we showed that glycerol trivalerate-
treated mice had significantly reduced C difficile TVC compared to PBS-treated control mice (95% 
reduction in glycerol-trivalerate treated mice after 3 doses). The results from our study are 
consistent with the previously published study by Theriot and colleagues, who briefly mention that 
antibiotic-exposed mice (who were susceptible to CDI) had a 66-fold decrease in valerate compared 
to non-antibiotic controls (who were resistant to CDI).
6
 They also showed that antibiotic-exposed 
mice had increased levels of amino acids required for C difficile growth (including proline, a 
precursor to 5-aminovalerate) compared to non-antibiotic controls. Six weeks later, antibiotic-
exposed mice were fully-resistant to CDI following exposure to C difficile spores. As shown in the 
supplementary material of their paper, Theriot and colleagues found that valerate levels had 
partially recovered six weeks later, and were only 4.9-fold decreased in antibiotic-exposed mice 
compared to non-antibiotic controls.  
C difficile spores can persist following the cessation of antibiotics and germinate to vegetative 
cells which initiate disease relapse. In our study we found that TCA, a known potent germinant for C 
difficile spores,
5
 was increased during clindamycin dosing, remained elevated for several days after 
stopping clindamycin, and had a strong positive correlation with C difficile TVC. However, after 
stopping clindamycin and allowing chemostat communities to recover and stabilise, we found that 
bile acid levels recovered to pre-clindamycin levels and did not change with FMT treatment. We 
hypothesise that the transient increase in TCA found during and shortly after stopping clindamycin 
dosing stimulated C difficile spore germination, resulting in vegetative growth. Once clindamycin 
dosing stopped and the levels of TCA decreased to pre-clindamycin levels, C difficile spores had 
already germinated and were growing in their vegetative state which is no longer affected by the 
presence of TCA (as shown by Sorg and Sonnenshein
5
, and confirmed in our study using batch 
cultures). These results are also consistent with the previously published study by Theriot and 
colleagues, who showed that antibiotic-exposed mice (who were susceptible to CDI) had a 15-fold 
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increase in TCA compared to non-antibiotic controls (who were resistant to CDI).
6
 Six weeks later 
(when antibiotic-exposed mice were fully-resistant to CDI) the levels of TCA in antibiotic-exposed 
mice recovered to the levels found in non-antibiotic controls, suggesting there was insufficient levels 
of TCA to stimulate C difficile germination. Further discussion of bile acid data is included in the 
Supplementary Discussion. 
The first line of therapy for an initial episode of CDI is vancomycin/metronidazole therapy. These 
antibiotics kill C difficile vegetative cells, but C difficile spores can persist.
42
 If 
vancomycin/metronidazole therapy is stopped while these C difficile spores are present, the 
elevated levels of TCA (present following the cessation of antibiotics) will cause C difficile spore 
germination, and low levels of valerate will allow C difficile vegetative growth and therefore 
recurrent disease.  To prevent CDI initiation and relapse following the cessation of antibiotics, it is 
also important to maintain low levels of TCA in the gut. One way to accomplish this would be to 
ensure the maintenance of bile salt hydrolase enzymes during and after antibiotic exposure. These 
enzymes are produced by commensal gut bacteria and are responsible for deconjugating tauro- and 
glyco-conjugated bile acids. It has been proposed that antibiotics kill bile salt hydrolase-producing 
bacteria, resulting in the accumulation of TCA in the gut. Therefore, re-inoculation of bile salt 
hydrolase-producing bacteria with FMT may be responsible for degrading TCA present following the 
cessation of antibiotics, and prevent the germination of C difficile spores. A more controlled method 
of restoring bile salt hydrolase activity in the gut microbiomes of CDI patients could be to avoid the 
administration of live microorganisms by administering purified bile salt hydrolase enzyme 
preparations. 
We also found that succinate transiently increased in chemostat cultures with clindamycin 
dosing, but negatively correlated with C difficile TVC. We believe the negative correlation between C 
difficile TVC and succinate is because C difficile uses succinate for growth. A study by Ferreyra and 
colleagues found that succinate was present at low levels in the guts of healthy mice, but transiently 
increased with antibiotics or motility disturbance.
8
 They found that C difficile can metabolise 
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succinate to butyrate, and it exploits the increase in succinate to grow in perturbed gut microbiota. 
Again, these findings are consistent with our findings from chemostat experiments. Members of 
Bacteroidetes and the Negativicutes class of Firmicutes can degrade succinate to propionate, and as 
such succinate does not usually accumulate to high levels in the guts of healthy humans.
43
 Another 
strategy to give C difficile vegetative cells a competitive disadvantage would be to maintain succinate 
metabolism during antibiotic exposure by administering succinate-degrading enzymes, so succinate 
is no longer available for C difficile growth.  
The findings from our study support the hypothesis that antibiotic exposure causes a depletion of 
specific metabolic pathways normally found in healthy gut microbiotas, resulting in a metabolite 
environment that favours C difficile germination and growth. It also supports our hypothesis that 
FMT administration reverses these effects by restoring the bacteria responsible for performing these 
key metabolic functions. These findings have the potential to directly impact clinical practice in the 
foreseeable future by developing targeted treatments for CDI by different routes, alone or in 
combinations: (1) directly supplement the gut with valerate (to inhibit C difficile vegetative growth); 
(2) directly supplement the gut with bile salt hydrolase enzymes (to degrade taurocholic acid and 
prevent C difficile spore germination); and (3) directly supplement the gut with succinate-degrading 
enzymes (to degrade succinate and give C difficile vegetative cells a competitive disadvantage). 
These proposed interventions are well-defined and represent safer options that will avoid all the 
risks involved with administering live microorganisms to patients and will not promote antimicrobial 
resistance.  
The advantage of using valerate (instead of live microorganisms or relatively undefined FMT 
preparations) is that valerate is a well-defined small molecule that is normally present in the healthy 
gut. Valerate may be a preferred treatment for CDI in immunocompromised patients where 
administration of bacteria may increase the risk of a subsequent infection, or in CDI patients that 
require further antibiotic treatment for other purposes (where the antibiotic treatment would kill 
bacteria present in FMT preparations and render the treatment less effective). Valerate could also 
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be delivered using more patient-friendly methods that do not require the need to preserve live 
microorganisms. In this study glycerol trivalerate was orally gavaged to mice, but it has also been 
included as an additive in animal feed. Therefore, valerate has the potential to be administered to 
patients via a less invasive route compared to FMT. This promising new therapy merits further 
evaluation in prospective studies in vivo.  
 
REFERENCES: 
1. Mitu-Pretorian OM, Forgacs B, Qumruddin A, et al. Outcomes of patients who develop 
symptomatic Clostridium difficile infection after solid organ transplantation. Transplant Proc 
2010;42:2631-2633. 
2. Ma GK, Brensinger CM, Wu Q, et al. Increasing incidence of multiply recurrent Clostridium difficile 
infection in the united states: a cohort study. Ann Intern Med 2017;167:152-158. 
3. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent 
Clostridium difficile. N Engl J Med 2013;368:407-415. 
4. Petrof EO, Gloor GB, Vanner SJ, et al. Stool substitute transplant therapy for the eradication of 
Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2013;1:3-2618-1-3. 
5. Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J 
Bacteriol 2008;190:2505-2512. 
6. Theriot CM, Koenigsknecht MJ, Carlson PE,Jr, et al. Antibiotic-induced shifts in the mouse gut 
microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat 
Commun 2014;5:3114. 
7. Weingarden AR, Chen C, Bobr A, et al. Microbiota transplantation restores normal fecal bile acid 
composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol 
2014;306:G310-9. 
8. Ferreyra JA, Wu KJ, Hryckowian AJ, et al. Gut microbiota-produced succinate promotes C difficile 
infection after antibiotic treatment or motility disturbance. Cell Host Microbe 2014;16:770-777. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
22 
 
9. Ott SJ, Waetzig GH, Rehman A, et al. Efficacy of sterile fecal filtrate transfer for treating patients 
with Clostridium difficile infection. Gastroenterology 2017;152:799-811.e7. 
10. De Filippo C, Cavalieri D, Di Paola M, et al. Impact of diet in shaping gut microbiota revealed by a 
comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 
2010;107:14691-14696. 
11. Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their 
impact on human metabolism. Gut Microbes 2016;7:189-200. 
12. McDonald JAK. In vitro models of the human microbiota and microbiome. Emerging Topics in Life 
Sciences 2017;1:373-384. 
13. Macfarlane GT, Macfarlane S. Models for intestinal fermentation: association between food 
components, delivery systems, bioavailability and functional interactions in the gut. Curr Opin 
Biotechnol 2007;18:156-162. 
14. McDonald JA, Schroeter K, Fuentes S, et al. Evaluation of microbial community reproducibility, 
stability and composition in a human distal gut chemostat model. J Microbiol Methods 
2013;95:167-174. 
15. Van den Abbeele P, Grootaert C, Marzorati M, et al. Microbial community development in a 
dynamic gut model is reproducible, colon region specific, and selective for Bacteroidetes and 
Clostridium cluster IX. Appl Environ Microbiol 2010;76:5237-5246. 
16. Freeman J, Baines SD, Jabes D, et al. Comparison of the efficacy of ramoplanin and vancomycin in 
both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J 
Antimicrob Chemother 2005;56:717-725. 
17. Baines SD, O'Connor R, Saxton K, et al. Comparison of oritavancin versus vancomycin as 
treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human 
gut model. J Antimicrob Chemother 2008;62:1078-1085. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
23 
 
18. Chilton CH, Crowther GS, Freeman J, et al. Successful treatment of simulated Clostridium difficile 
infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole 
failure. J Antimicrob Chemother 2014;69:451-462. 
19. Chilton CH, Crowther GS, Baines SD, et al. In vitro activity of cadazolid against clinically relevant 
Clostridium difficile isolates and in an in vitro gut model of C difficile infection. J Antimicrob 
Chemother 2014;69:697-705. 
20. Meader E, Mayer MJ, Steverding D, et al. Evaluation of bacteriophage therapy to control 
Clostridium difficile and toxin production in an in vitro human colon model system. Anaerobe 
2013;22:25-30. 
21. Chilton CH, Crowther GS, Spiewak K, et al. Potential of lactoferrin to prevent antibiotic-induced 
Clostridium difficile infection. J Antimicrob Chemother 2016;71:975-985. 
22. Freeman J, Baines SD, Saxton K, et al. Effect of metronidazole on growth and toxin production by 
epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob 
Chemother 2007;60:83-91. 
23. Mullish BH, Marchesi JR, Thursz MR, et al. Microbiome manipulation with faecal microbiome 
transplantation as a therapeutic strategy in Clostridium difficile infection. QJM 2015;108:355-359. 
24. Illumina I. 16S Metagenomic Sequencing Library Preparation (Part # 15044223 Rev. B); 2013. 
Available at: https://support.illumina.com/content/dam/illumina-
support/documents/documentation/chemistry_documentation/16s/16s-metagenomic-library-
prep-guide-15044223-b.pdf, 2017. 
25. Weljie AM, Newton J, Mercier P, et al. Targeted profiling: quantitative analysis of 
1
H NMR 
metabolomics data. Anal Chem 2006;78:4430-4442. 
26. Sarafian MH, Lewis MR, Pechlivanis A, et al. Bile acid profiling and quantification in biofluids 
using ultra-performance liquid chromatography tandem mass spectrometry. Anal Chem 
2015;87:9662-9670. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
24 
 
27. Kao D, Roach B, Silva M, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota 
transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 
2017;318:1985-1993. 
28. Garcia-Villalba R, Gimenez-Bastida JA, Garcia-Conesa MT, et al. Alternative method for gas 
chromatography-mass spectrometry analysis of short-chain fatty acids in faecal samples. J Sep Sci 
2012;35:1906-1913. 
29. Winston JA, Thanissery R, Montgomery SA, et al. Cefoperazone-treated mouse model of 
clinically-relevant Clostridium difficile strain R20291. J Vis Exp 2016;(118). doi:10.3791/54850. 
30. Wolfer A. SANTA-App: Interactive package for Short AsyNchronous Time-series Analysis (SANTA) 
in R, implemented in Shiny; 2017. Available at: https://github.com/adwolfer/SANTA-App, 2017. 
31. Le Cao K, Rohart F, Gonzalez I, et al. mixOmics: Omics Data Integration Project. R package version 
6.1.2.; 2017. Available at: https://CRAN.R-project.org/package=mixOmics, 2017. 
32. Schwartz B. The effect of temperature on the rate of hydrolysis of triglycerides by pancreatic 
lipase. J Gen Physiol 1943;27:113-118. 
33. Neis EP, Dejong CH, Rensen SS. The role of microbial amino acid metabolism in host metabolism. 
Nutrients 2015;7:2930-2946. 
34. Barker HA, D'Ari L, Kahn J. Enzymatic reactions in the degradation of 5-aminovalerate by 
Clostridium aminovalericum. J Biol Chem 1987;262:8994-9003. 
35. Seto B, Stadtman TC. Purification and properties of proline reductase from Clostridium 
sticklandii. J Biol Chem 1976;251:2435-2439. 
36. Hodgins DS, Abeles RH. Studies of the mechanism of action of D-proline reductase: the presence 
on covalently bound pyruvate and its role in the catalytic process. Arch Biochem Biophys 
1969;130:274-285. 
37. Seto B. The Stickland reaction. In: Knowles CJ, ed. Diversity of Bacterial Respiratory Systems (Vol. 
II). Boca Raton, FL: CRC Press, 1980:49-64. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
25 
 
38. Buckel W. Unusual enzymes involved in five pathways of glutamate fermentation. Appl Microbiol 
Biotechnol 2001;57:263-273. 
39. Savidge T, Dann S. Methods and uses for metabolic profiling for Clostridium difficile infection. 
2013;PCT/US2012/064218. 
40. Fletcher JR, Erwin S, Lanzas C, et al. Shifts in the gut metabolome and Clostridium difficile 
transcriptome throughout colonization and infection in a mouse model. mSphere 
2018;3:10.1128/mSphere.00089-18. eCollection 2018 Mar-Apr. 
41. Bornstein BT, Barker HA. The energy metabolism of Clostridium kluyveri and the synthesis of 
fatty acids. J Biol Chem 1948;172:659-669. 
42. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev 
Gastroenterol Hepatol 2011;9:88-96. 
43. Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environ 
Microbiol 2017;19:29-41. 
  
Author names in bold designate shared co-first authorship. 
 
FIGURE LEGENDS: 
Figure 1: Average C difficile plate counts taken from VA (saline-treated cultures, black dashed line) 
and VB (FMT-treated cultures, black solid line) over the course of the experiment. (A) Average C 
difficile total viable counts. (B) Average C difficile spore plate counts. The grey shaded box indicates 
the clindamycin-dosing period, while the vertical dotted line indicates the day of FMT or saline 
dosing. Error bars represent the mean ± standard deviation (*, p<0.05 by SANTA analysis). 
Figure 2: 
1
H-NMR metabolites that changed following clindamycin treatment and with FMT (VA= 
saline-treated cultures, dashed line; VB= FMT-treated cultures, solid line).  (A) valerate, (B) 5-
aminovalerate, (C) ethanol, (D) succinate, (E) propionate, and (F) methanol. The shaded grey box 
indicates the clindamycin-dosing time period, while the vertical dotted line indicates the day of FMT 
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or saline dosing. SANTA analysis with Benjamini-Hochberg FDR was used to compare the following: 
steady state cultures to clindamycin-treated cultures, steady state cultures to post-clindamycin 
cultures, and FMT-treated cultures to saline treated cultures. 
Figure 3: Bile acids that changed following clindamycin treatment and correlated with C difficile TVC 
(VA= saline-treated cultures, dashed line; VB= FMT-treated cultures, solid line).  (A) taurocholic acid 
(TCA), (B) cholic acid (CA), (C) deoxycholic acid (DCA), and (D) lithocholic acid (LCA). The shaded grey 
box indicates the clindamycin-dosing period, while the vertical dotted line indicates the day of FMT 
or saline dosing. Steady state cultures were compared to clindamycin-treated cultures using SANTA 
analysis with Benjamini-Hochberg FDR. 
Figure 4: Effect of FMT on the concentration of valerate in stool from healthy FMT donors (n=5) and 
recurrent CDI patients pre-FMT (n=16) and at several time points post-FMT (n=16). Mann-Whitney U 
test for donors vs. pre-FMT, Friedman test for pre-FMT vs. post-FMT. ** p<0.01, *** p<0.001. 
Figure 5: Valerate inhibits C difficile vegetative growth in batch cultures. Vegetative cells were 
inoculated into supplemented brain heart infusion broth containing varying concentrations of 
valerate (0, 1, 2, 3, 4, 5, 10, and 20 mM) and OD600 measurements were taken at 0, 2, 4, 6, and 8 
hours. The change in OD600 (from a time point during the exponential phase) was plotted against the 
concentrations of valerate tested. (A) C difficile ribotype 010, (B) C difficile ribotype 012, (C) C 
difficile ribotype 027, (D) B. uniformis, (E) B. vulgatus, (F) C. scindens. Error bars represent the mean 
± standard deviation, * p<0.05, ** p<0.01, *** p<0.001. 
Figure 6: Glycerol trivalerate significantly reduced faecal C. difficle total viable counts in a CDI mouse 
model. (A) Experimental design. Mice were given cefoperazone in their drinking water for 5 days, 
then switched to antibiotic-free autoclaved water for the remainder of the experiment. On day 0 
mice were orally gavaged with 10
5
 CFU of C difficile spores. On days 1, 2, and 3 mice were orally 
gavaged with glycerol trivalerate (n=5) or PBS (n=5). (B) C difficile TVC were quantified from mouse 
faecal pellets on days 1, 2, 3, and 4. The box excludes the upper and lower 25% (quartiles) of data, 
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and the lines go to maximum and minimum values. All data points are marked with “ᴏ” in the plot. 
Independent t-test of log10-transformed C difficile TVC, *p<0.05, ** p<0.01. 
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Table 1: Time periods used for CDI chemostat experiments to compare the effects of FMT to saline. 
Vessel Days 0-17 Days 18-24 Day 24 Days 25-31 Days 32-42 Day 42 Days 43-54 
Control 
vessel 
(VA) 
Stabilisation 
period  
(no intervention) 
Stable 
communities  
(no intervention) 
Added      
C difficile 
spores 
Added C difficile 
spores (day 25) and 
clindamycin every  
12 hrs (days 25-31) 
Stabilisation 
period  
(no intervention) 
Added 
saline 
No 
intervention 
Test 
vessel 
(VB) 
Stabilisation 
period  
(no intervention) 
Stable 
communities  
(no intervention) 
Added     
C difficile 
spores 
Added C difficile 
spores (day 25) and 
clindamycin every  
12 hrs (days 25-31) 
Stabilisation 
period  
(no intervention) 
Added 
FMT 
No 
intervention 
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SUPPLEMENTARY MATERIAL 
SUPPLEMENTARY METHODS: 
Bacterial strains:  
C difficile DS1684 (ribotype 010, non-toxigenic strain) was used for chemostat experiments and 
mouse experiments. C difficile DS1684, C difficile CD630 (ribotype 012, virulent multidrug resistant 
strain), C difficile R20291 (ribotype 027, a hypervirulent strain), Bacteroides uniformis, Bacteroides 
vulgatus, and Clostridium scindens (DSM 5676) were used in batch culture experiments. C difficile 
ribotype 027 is a common ribotype in Europe and North America,
1-3
 while ribotype 012 is one of the 
common ribotypes in mainland China.
4,5
 CD630 and R20291 are genetically and phenotypically well-
characterised and are good representatives of their ribotypes.
6
 B uniformis and B vulgatus were isolated 
from the stool of a healthy male in his 30’s using fastidious anaerobe agar (Lab M, Heywood, UK) or 
nutrient agar (Sigma-Aldrich, St. Louis, USA), respectively. 
 
Chemostat model of CDI: 
The working volume of each vessel was 235 ml and the growth medium feed was set to a retention 
time of 21 hours.
7,8
 The composition of the growth medium consisted of a mixture of both soluble and 
insoluble starches, amino acids, peptides, proteins, vitamins, trace elements, and porcine gastric mucin 
(type II).
9
 To mimic the gut environment cultures were maintained at a temperature of 37ᵒC and a pH of 
6.8, were gently agitated, and kept anaerobic by sparging with oxygen-free nitrogen gas. Chemostat 
cultures were sampled daily from each vessel and vessels were operated for 54 days post-inoculation. 
Chemostat culture samples were aliquoted and stored at -80ᵒC for DNA extraction and mass 
spectrometry analysis. For NMR analysis, fresh chemostat culture was centrifuged at 20,000 x g and 4ᵒC 
for 10 minutes, and the supernatant was aliquoted and stored at -80ᵒC.  
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Design of chemostat experiments: 
We induced CDI in our chemostat gut model following a modified version of the methods previously 
described by Freeman and colleagues (Table 1).
10
 Briefly, chemostat cultures were grown for 24 days 
without experimental manipulation to allow the communities to stabilise. After sampling vessels on day 
24 we added 7.8x10
6
 C difficile spores to each vessel to achieve an initial concentration of 3.3x10
4
 
spores/mL.
11
 On day 25 we added another dose of 7.8x10
6
 C difficile spores to both vessels, and 
clindamycin was added to both vessels at a final concentration of 33.9 mg/L every 12 hours for 7 days 
(from days 25-31). After stopping clindamycin dosing chemostat cultures were left to grow for 10 days 
without experimental manipulation (days 32-42). This was done to allow the perturbed microbial 
communities to stabilise, so we could more easily determine which bacteria or metabolites were altered 
by FMT, and which bacteria or metabolites were able to recover after antibiotic treatment in the 
absence of FMT. After sampling on day 42 we added a single dose of saline to VA (control vessel) and a 
single dose of FMT to VB (test vessel). Chemostat cultures were then left to grow for a further 12 days 
without further experimental manipulation to monitor the effects of FMT on the chemostat 
communities (days 43-54).  
 
C difficile spore preparation: 
C difficile spores were prepared using previously described methods.
11
 C difficile DS1684 was grown 
anaerobically on fastidious agar plates supplemented with 5% defibrinated horse blood (VWR, Radnor, 
USA) and incubated at 37ᵒC for 7 days. The growth was removed from the plates using a sterile loop and 
resuspended in 1 mL sterile water. Next, 1 mL of 95% ethanol was mixed with the cell suspension and 
was incubated for 1 hour at room temperature. The cell suspension was then centrifuged at 3000 x g 
and resuspended in 1 mL sterile water. Spores were enumerated by preparing serial 10-fold dilutions in 
phosphate buffered saline (PBS) (Sigma-Aldrich) and plating the dilutions on Braziers Cycloserine, 
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Cefoxitin Egg Yolk agar plates (containing Braziers CCEY agar base (Lab M), 250 mg/L cycloserine (VWR), 
8 mg/L cefoxitin (Sigma-Aldrich), 8% egg yolk emulsion (SLS, Nottingham UK), 2% lysed defibrinated 
horse blood (VWR), and 5 mg/L lysozyme (Sigma-Aldrich)).
12
 Plates were incubated anaerobically at 37ᵒC 
for 48 hours and the number of colonies were enumerated.  
 
Enumeration of C difficile counts from chemostat culture samples: 
C difficile total viable counts and spore counts were quantified from fresh chemostat culture samples 
every other day starting 26 days post-inoculation. C difficile total viable counts (TVC) were enumerated 
from fresh chemostat culture samples by performing serial 10-fold dilutions in PBS and plating onto 
Brazier’s Cycloserine, Cefoxitin Egg Yolk agar plates (as described above, with the addition of 2 mg/L 
moxifloxacin (VWR)) in triplicate using the Miles and Misra method.
13
 C difficile spore counts were 
enumerated from alcohol-shocked chemostat culture samples by mixing an equal volume of fresh 
chemostat culture sample with 95% ethanol and incubating at room temperature for one hour. Samples 
were then centrifuged at 3000 x g and 4ᵒC for 10 minutes and resuspended in PBS. Spores were then 
quantified by performing serial 10-fold dilutions in PBS and plating onto Brazier’s Cycloserine, Cefoxitin 
Egg Yolk agar plates (as described above, without the addition of moxifloxacin) in triplicate using the 
Miles and Misra method. Plates were incubated anaerobically at 37ᵒC for two days and colonies were 
enumerated. 
 
Preparation and instillation of FMT: 
Fresh faecal samples were placed into an anaerobic chamber within 5 minutes of defecation. FMT 
preparations were prepared by homogenising 10 g of stool in 100 mL of anaerobic 0.9% saline in a 
strainer stomacher bag (250 rpm for 1 min). We added 50 mL of anaerobic saline to VA (control vessel) 
and 50 mL of homogenised stool to VB (test vessel). For Run 1 and Run 2 the stool transplant was 
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prepared from the stool of a healthy male donor in his 30’s, and for Run 3 the stool transplant was 
prepared from the stool of a healthy female donor in her 20’s. Both individuals have been used as FMT 
donors to treat CDI patients in Imperial’s FMT Programme (and therefore undergone the appropriate 
donor screening protocols), and had not taken antibiotics for at least 3 months prior to providing the 
stool sample. 
 
DNA extraction:  
DNA was extracted from 250 µL of chemostat culture using the PowerLyzer PowerSoil DNA Isolation 
Kit (Mo Bio, Carlsbad, USA) following the manufacturer’s protocol, except that samples were lysed by 
bead beating for 3 min at speed 8 using a Bullet Blender Storm instrument (Chembio Ltd, St. Albans, UK). 
DNA was aliquoted and stored at -80ᵒC until it was ready to be used.  
 
16S rRNA gene qPCR: 
16S rRNA gene qPCR data was used to determine the total bacterial biomass within each sample and 
was performed using extracted chemostat culture DNA to following a previously published protocol.
14
 A 
total volume of 20 µL was used for each reaction and consisted of the following: 1x Platinum Supermix 
with ROX (Life Technologies, Carlsbad, USA), 1.8 µM BactQUANT forward primer (5’-
CCTACGGGAGGCAGCA-3’), 1.8 µM BactQUANT reverse primer (5’-GGACTACCGGGTATCTAATC-3’), 225 
nM probe ((6FAM) 5’-CAGCAGCCGCGGTA-3’ (MGBNFQ)), PCR grade water (Roche, Penzberg, Germany), 
and 5 µL DNA. Each PCR plate included a standard curve using E. coli DNA (Sigma-Aldrich) (3-300,000 
copies per reaction in 10-fold serial dilutions) as well as no template negative controls. All samples, 
standards, and controls were amplified in triplicate. Extracted DNA samples were diluted to ensure they 
fell within the standard curve. Amplification and real-time fluorescence detections were performed 
using the Applied Biosystems StepOnePlus Real-Time PCR System using the following PCR cycling 
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conditions: 50 °C for 3 min, 95 °C for 10 min, and 40 cycles of 95 °C for 15 sec and 60 °C for 1 min. We 
used a paired t-test to compare changes in log-transformed 16S rRNA gene copy number between 
samples at specific time points. 
 
Pre-processing and analysis of 16S rRNA gene sequencing data: 
We used the Mothur package (v1.35.1) to preprocess and analyse the resulting sequencing data 
following the MiSeq SOP Pipeline.
15
 We used the Silva bacterial database for sequence alignments 
(www.arb-silva.de/) and the RDP database reference sequence files for classification of sequences using 
the Wang method.
16
 We determined the Operational Taxonomic Unit (OTU) taxonomies (phylum to 
genus) using the RDP MultiClassifier script. We resampled and normalised data to the lowest read count 
in Mothur (9527 reads per sample), which resulted in greater than 99.4% coverage within each sample. 
We used 16S rRNA gene qPCR data and the following formula to express our 16S rRNA gene sequencing 
data as absolute abundances (instead of relative abundances): 
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The Shannon diversity index (H’), Pielou evenness index (J’), and richness (total number of bacterial 
taxa observed, Sobs) were calculated using the vegan library
17
 within the R statistical package.
18
 
Stream plots were prepared by plotting the absolute abundance of 16S rRNA gene sequencing data 
(biomass-corrected) over time (OTU-level, coloured by phylum). This was accomplished using the 
streamgraph function within the streamgraph library (v0.8.1) within R.
19
  
 
1
H-NMR spectroscopy sample preparation: 
Chemostat culture supernatants were randomized and defrosted at room temperature for 1 hour. 
Once samples were defrosted supernatants were centrifuged at 20,000 x g and 4ᵒC for 10 minutes. Next, 
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400 µL of chemostat culture supernatant was mixed with 250 µL of sodium phosphate buffer solution 
(28.85 g Na2HPO4 (Sigma-Aldrich), 5.25 g NaH2PO4 (Sigma-Aldrich), 1 mM TSP (Sigma-Aldrich), 3 mM 
NaN3 (Sigma-Aldrich), deuterium oxide (Goss Scientific Instruments, Crewe, UK) to 1 L, pH 7.4)
20
 and 600 
µL was pipetted into a 5 mm NMR tube. 
 
Confirmation of NMR metabolite identities using 1D-NMR with spike-in and 2D-NMR spectroscopy: 
We used the statistical total correlation spectroscopy (STOCSY) analysis method to aid in the 
identification of metabolites in NMR spectra by determining correlations between intensities of the 
various peaks across the whole sample.
21
 To further confirm if the peaks assigned to valerate and other 
metabolites were correct, we also conducted a two-dimensional NMR spectra (including 
1
H−
1
H TOCSY 
and 
1
H−
1
H COSY) for the chemostat culture supernatant and valerate standard using typical parameters 
to confirm the connectivity of the proton in the metabolites.
22,23
 
For the valerate spike-in experiment one-dimensional 
1
H NMR spectra were acquired as described in 
the 
1
H-NMR spectroscopy methods section from the main text, except 64 scans were recorded into 
65536 data points with a spectral width of 20 ppm. After normal 1D 
1
H NOESY NMR acquisition, 10 µL of 
valerate standard (99%, 0.9 M in PBS buffer) (Fisher Scientific, Hampton, USA) was added into the 
sample. A one-dimensional spectrum was recorded again to see if the relevant peaks of valerate 
increased.  
 
Data pre-processing and analysis of UPLC-MS bile acid data: 
Quality control samples were prepared using a mixture of equal parts of the chemostat culture 
supernatants.  We used the quality control samples as an assay performance monitor and to guide the 
removal of features with high variation.24 We also spiked quality control samples with defined mixtures 
of bile acids to determine the chromatographic retention times of specific bile acids and to aid in 
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metabolite identification (55 bile acid standards, including 36 non-conjugated bile acids, 12 tauro-
conjugated bile acids, and 7 glyco-conjugated bile acids) (Steraloids, Newport, USA). 
We converted the Waters raw data files to NetCDF format and extracted the data using XCMS (v1.50) 
package implemented within the R (v3.3.1) software. Dilution effects were corrected for using 
probabilistic quotient normalisation
25
 and chromatographic features with high coefficient of variation 
(higher than 30% in the quality control samples) were excluded from further analysis. 
 
Short AsyNchronous Time-series Analysis (SANTA): 
SANTA is an automated pipeline that is implemented within R and controlled through a graphical 
user interface developed with Shiny. 
26,27
 This method analyses short time series by estimating 
trajectories as a smooth spline, and calculates whether time trajectories are significantly altered 
between different groups or over different time periods. SANTA was used to make the following 
comparisons: stabilisation period vs. clindamycin-dosing period, stabilisation period vs. post-clindamycin 
stabilisation period, and FMT-treated vs. saline-treated cultures during the treatment period. We used 
mean subtraction to eliminate between-run differences in metabolite concentrations that arose from 
differences in the stool used to seed the chemostat vessels. For each metabolite, we calculated the 
mean for all samples within the same chemostat run, then we subtracted the mean from all its values 
within the run.
28
 Depending upon the time series being analysed, the number of degrees of freedom (df) 
to fit the spline model was chosen to avoid overfitting the data (df = 3-5). We report the pDist values, 
which uses the area between the mean group fitted curves to determine whether there is a difference 
between the two groups over time. Analysis used 1000 permutation rounds to calculate p-values and 
1000 bootstrap rounds to calculate the 95% confidence bands. Reported pDist values are with Benjamini-
Hochberg FDR correction, and p < 0.05 was considered significant. 
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Integration of 16S rRNA gene sequencing data and metabolite data: 
We used regularised Canonical Correlation Analysis (rCCA) to correlate 16S rRNA gene sequencing 
data (genus level) with bile acid mass spectrometry or 
1
H-NMR data from the same set of samples using 
the mixOmics library within R.
29
 rCCA is an unsupervised method that maximises the correlation 
between the two data sets X and Y (information on the treatment groups is not taken into account in 
the analysis). We used the shrinkage method to determine the regularisation parameters. The plotIndiv 
function was used to generate unit representation plots, where each point on the scatter plot 
represents a single chemostat culture sample, and samples were projected into the XY-variate space. 
The plotVar function was used to generate correlation circle plots, where strong correlations between 
variables (correlations greater than 0.5) are plotted outside of the inner circle. Variables are represented 
through their projections onto the planes defined by their respective canonical variates. In this plot the 
variables projected in the same direction from the origin have a strong positive correlation, and 
variables projected in opposite directions form the origin have strong negative correlations. Variables 
with stronger correlations sit at farther distances from the origin. 
 
C difficile germination batch cultures with taurocholic acid (TCA): 
To test the effects of TCA on C difficile germination we resuspended C difficile DS1684 spores in 
supplemented brain heart infusion broth with or without 1% TCA (Sigma-Aldrich) in triplicate.
30
 The 
OD600 was measured immediately after inoculation of broths (time zero) and after an overnight 
incubation at 37ᵒC in anaerobic chamber. A paired t-test was used to determine whether TCA affected C 
difficile germination. 
 
C difficile vegetative growth batch cultures with TCA: 
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To test the effects of TCA on C difficile vegetative growth we centrifuged an overnight culture of C 
difficile DS1684 at 3000 x g for 10 minutes and resuspended the cells in supplemented brain heart 
infusion broth with or without 1% TCA (in triplicate). The OD600 was measured at time zero and cultures 
were incubated at 37ᵒC in an anaerobic chamber. Additional OD600 measurements were taken at 2, 4, 6, 
and 8 hours post-inoculation, and the change in OD600 was plotted against time. A paired t-test was used 
to determine whether TCA affected vegetative growth during the exponential phase. 
 
SUPPLEMENTARY RESULTS: 
C difficile total viable counts and spore counts: 
There was no significant difference in C difficile TVC at the end of the clindamycin-dosing period 
compared to TVC immediately prior to administering FMT or saline treatment (p>0.05). There was also 
no significant difference in C difficile TVC in vessels assigned to receive FMT or saline treatment 
immediately prior to administering the treatment (p>0.05). 
 
1
H-NMR spectroscopy: 
Following FMT or saline treatment there were significant strong negative correlations between 
valerate and 5-aminovalerate (rS=-0.76, p=5.27x10
-6
), ethanol (rS=-0.69, p=6.53x10
-5
), and methanol (rS=-
0.78, p=3.11x10
-6
). 
 
Confirmation of valerate in chemostat culture supernatant by 1D- and 2D-NMR: 
The chemical shifts for the 1D 
1
H-NMR spectrum of 99% valerate standard were: 0.9 (t), 1.3 (dt), 1.46 
(m), 2.2 (t) (Figure S5A). Overlay of the 1D 1H-NMR spectrum of the valerate standard with the sample 
showed that each peak of the valerate standard is visible in the sample (Figure S5B). Overlay of 1D 1H-
NMR spectra of the sample before and after valerate spike-in showed that all the valerate peaks 
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increased after spike-in (Figure S5C). For 2D-NMR analysis overlay of the 
1
H-
1
H COSY spectrum of the 
valerate standard with the sample showed that each peak of the valerate standard was present in the 
sample spectrum (Figure S6A). Overlay of 
1
H-
1
H TOCSY spectrum of the valerate standard with the 
sample showed that each peak of the valerate standard was present in the sample spectrum (Figure 
S6B). 
 
SUPPLEMENTARY DISCUSSION: 
Valerate is not expected to be harmful to host gut cells, as exposure of gut organoids to 5 mM 
valerate did not result in cell death or cause significant alterations in gene expression (Drs. Lee Parry and 
Richard Brown of the European Cancer Stem Cell Research Institute, personal communication, 19 Dec. 
2017). Moreover, mice that received 15 mM glycerol trivalerate in our study did not show any adverse 
reactions. 
The bacterial enzyme 7-α-dehydroxylase is responsible for converting unconjugated primary bile 
acids CA and CDCA to the secondary bile acids DCA and LCA, respectively. DCA and LCA have been 
shown to inhibit C difficile vegetative growth at specific concentrations,
30,31
 and a previous study has 
shown that DCA and LCA were depleted in pre-FMT samples from recurrent CDI patients, but were 
restored in post-FMT samples.
32
 These findings led researchers to propose antibiotic exposure results in 
the loss of bacteria with 7-α-dehydroxylase activity, reducing DCA and LCA production and permitting C 
difficile vegetative growth. A study by Buffie and colleagues found that administration of Clostridium 
scindens (a bacterium with 7-α-dehydroxylase activity) was associated with resistance to C difficile by 
restoring the production of the secondary bile acids DCA and LCA.
33
 However, in our study we found that 
the levels of DCA and LCA recovered in chemostat cultures following the cessation of clindamycin. While 
we did find strong negative correlations between C difficile TVC and the secondary bile acids DCA and 
LCA, recovery of these bile acids to pre-clindamycin levels was not enough to decrease vegetative C 
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difficile counts in chemostat cultures. Indeed, while DCA can inhibit C difficile vegetative growth, it 
appears that DCA can also encourage spore germination at specified concentrations.
30
 A better strategy 
to prevent CDI prior to antibiotic exposure would be to prevent germination altogether by degrading 
TCA, a potent pro-germinant, using bile salt hydrolase enzymes. 
Our chemostat experiments more closely modelled the first episode of CDI and not recurrent CDI. In 
first episodes of CDI, human patients are exposed to C difficile spores while taking an inciting antibiotic 
(e.g. clindamycin). In our study clindamycin exposure was sufficient to deplete valerate and elevate 
levels of TCA, allowing C difficile spore germination and vegetative growth. We waited 10 days after 
stopping clindamycin dosing before administering the FMT preparation to allow the perturbed microbial 
communities to stabilise following the cessation of antibiotics. This delay allowed us to more easily 
determine which metabolites were altered only by FMT, and which metabolites were able to recover 
after antibiotic treatment (in the absence of FMT). This feature is a major advantage of performing 
chemostat studies, as it would be unethical to withhold treatment from recurrent CDI patients in human 
studies to determine which metabolites would recover in the absence of FMT. We found no significant 
difference in C difficile TVC at the end of the clindamycin-dosing period compared to TVC immediately 
prior to administering FMT or saline treatment (see Supplementary Results). This means the metabolites 
that recovered following the cessation of clindamycin dosing, but before FMT, did not affect the 
vegetative growth of C difficile (i.e. bile acids). However, we did see a significant decrease in C difficile 
TVC and spore counts after FMT. This decrease suggests that bacterial metabolites that decreased C 
difficile counts did not recover after stopping clindamycin, but only recovered with FMT (i.e. valerate).  
Most human studies of CDI have focused on recurrent CDI, not first episode of CDI. In this study we 
showed that valerate was depleted in recurrent CDI patients pre-FMT, but was restored post-FMT. To 
our knowledge this is the first study to measure valerate in the stool of recurrent CDI patients pre- and 
post-FMT. A previous study by Weingarden and colleagues found that TCA was elevated in the stool of 
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recurrent CDI patients pre-FMT, but was decreased post-FMT.
32
 It is important to note that in these 
human studies recurrent CDI patients were taking vancomycin when pre-FMT samples were collected, 
and FMT was administered to recurrent CDI patients within 1-2 days of stopping vancomycin therapy. 
While we could have designed our chemostat experiments to also include a vancomycin dosing regimen, 
followed by FMT administration 1-2 days later, broad-spectrum vancomycin therapy would have killed 
more gut bacteria and depleted the chemostat cultures of additional ecosystem functions that were not 
important for the establishment of the infection, leading to false positives once these functionalities 
were restored following FMT. In our chemostat experiments FMT was administered 10 days after 
stopping clindamycin and pre-FMT samples were collected immediately prior to FMT administration. 
Had we chosen to administer the FMT preparation within 1-2 days after stopping clindamycin we would 
expect TCA levels to decrease with FMT. 
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SUPPLEMENTARY FIGURE LEGENDS: 
Figure S1: Stream plots showing the OTU abundances in each chemostat culture over time. Each stream 
of colour represents an OTU, and streams are grouped by phylum: Bacteroidetes (blue), Firmicutes 
(green), Proteobacteria (orange), Verrucomicrobia (purple), unclassified (grey), and C difficile (red). The 
width of the stream represents the OTU abundance at each time point. The dotted box indicates the 
clindamycin-dosing period, while the dotted vertical line indicates the day of FMT or saline dosing. 
Figure S2: Diversity of bacterial communities cultured in chemostat vessels (VA= saline-treated cultures, 
dashed line; VB= FMT-treated cultures, solid line). (A) Shannon diversity index (H’), (B) Richness (Sobs), 
(C) Pielou’s evenness index (J’). The shaded grey box indicates the clindamycin-dosing period, while the 
vertical dotted line indicates the day of FMT or saline dosing. SANTA analysis with Benjamini-Hochberg 
FDR was used to compare the following: steady state cultures to clindamycin-treated cultures, steady 
state cultures to post-clindamycin cultures, and FMT-treated cultures to saline treated cultures. 
Figure S3: 
1
H-NMR metabolites that changed following clindamycin treatment and with FMT (VA= saline-
treated cultures, dashed line; VB= FMT-treated cultures, solid line).  (A) butyrate, (B) acetate, (C) 
isobutyrate, and (D) isovalerate. The shaded grey box indicates the clindamycin-dosing time period, 
while the vertical dotted line indicates the day of FMT or saline dosing. SANTA analysis with Benjamini-
Hochberg FDR was used to compare the following: steady state cultures to clindamycin-treated cultures, 
steady state cultures to post-clindamycin cultures, and FMT-treated cultures to saline treated cultures. 
Figure S4: Regularized CCA (rCCA) model correlating 16S rRNA gene sequencing data (genus-level) and 
1H-NMR metabolite data. (A) The representation of units (a.k.a. samples) for the first two canonical 
variates showing the correlations between variables before (grey), during (blue), and after (orange) the 
clindamycin-dosing period. “A” represents samples collected from VA and “B” represents samples from 
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VB. (B) Correlation circle plot showing strong correlations between variables before, during, and after 
the clindamycin-dosing period. Metabolites are shown in blue and bacterial genera are shown in orange. 
Clostridium cluster XI (the clostridial cluster that includes C difficile) is shown in a black box. (C) The 
representation of units (a.k.a. samples) for the first two canonical variates showing the correlations 
between variables following FMT (blue) or saline (orange) treatment. “A” represents samples collected 
from VA (saline-treated cultures) and “B” represents samples from VB (FMT-treated cultures). (D) 
Correlation circle plot showing strong correlations between variables following FMT or saline treatment. 
Metabolites are shown in blue and bacterial genera are shown in orange. Clostridium cluster XI (the 
clostridial cluster that includes C difficile) is shown in a black box. 
Figure S5: 1D 
1
H-NMR to confirm the identity of valerate in chemostat culture supernatants. (A) 1D 
1
H-
NMR spectrum of valerate standard (blue). (B) Overlay of 1D 
1
H-NMR spectrum of valerate standard 
(blue) with sample spectrum (red). Each peak of the valerate standard is visible in the sample spectrum. 
(C) Overlay of 1D 
1
H-NMR spectra of sample before (blue) and after (red) valerate spike-in. All the peaks 
proposed to belong to valerate increased following spike in with valerate standard (green). 
Figure S6: 2D 
1
H-NMR to confirm the identity of valerate in chemostat culture supernatants. (A) Overlay 
of the 
1
H-
1
H COSY spectrum of valerate standard (blue) with sample spectrum (red). Each peak of the 
valerate standard is visible in the sample spectrum. (B) Overlay of the 
1
H-
1
H TOCSY spectrum of valerate 
standard (blue) with sample spectrum (red). Again, each peak of the valerate standard is visible in the 
sample spectrum. 
Figure S7: Overlay of 
1
H-
1
H COSY sample spectrum (blue) and 
1
H-
1
H TOCSY sample spectrum (red) to 
confirm the identity of other metabolites found in chemostat culture supernatants.  
Figure S8: Statistical total correlation spectroscopy (STOCSY). (A) 5-aminovalerate STOCSY spectrum 
obtained by correlating all points in the spectra with the 5-aminovalerate resonance at 3.019 ppm. Peak 
clusters with high correlations (*) correspond to positions where we expected to see peaks for 5-
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aminovalerate. (B) Succinate STOCSY spectrum obtained by correlating all points in the spectra with the 
succinate resonance at 2.408 ppm. No other peaks had high correlations with the peak at 2.408, 
confirming this peak belonged to succinate.  
Figure S9: Bile acids that changed following clindamycin treatment (VA= saline-treated cultures, dashed 
line; VB= FMT-treated cultures, solid line). (A) taurodeoxycholic acid (TDCA), (B) glycocholic acid (GCA), 
(C) glycodeoxycholic acid (GDCA), (D) glycochenodeoxycholic acid (GCDCA), (E) chenodeoxycholic acid 
(CDCA), and (F) ursodeoxycholic acid (UDCA). The shaded grey box indicates the clindamycin-dosing 
period, while the vertical dotted line indicates the day of FMT or saline dosing. Steady state cultures 
were compared to clindamycin-treated cultures using SANTA analysis with Benjamini-Hochberg FDR. 
Figure S10: Regularized CCA (rCCA) model correlating 16S rRNA gene sequencing data (genus-level) and 
bile acid data. (A) The representation of units (a.k.a. samples) for the first two canonical variates 
showing the correlations between variables before (grey), during (blue), and after (orange) the 
clindamycin-dosing period. “A” represents samples collected from VA and “B” represents samples from 
VB. (B) Correlation circle plot showing strong correlations between variables before, during, and after 
the clindamycin-dosing period. Bile acids are shown in blue and bacterial genera are shown in orange. 
Clostridium cluster XI (the clostridial cluster that includes C difficile) is shown in a black box. 
Figure S11: TCA is required for C difficile spore germination, but has no effect on C difficile vegetative 
growth. (A) C difficile spores were incubated supplemented brain heart infusion broth in the presence 
and absence of 1% TCA and grown overnight. There was a significant increase in C difficile germination in 
the presence of TCA (*** p<0.001). (B) C difficile vegetative cells were inoculated into supplemented 
brain heart infusion broth in the presence and absence of 1% TCA. There were no significant differences 
in the growth of C difficile in the presence or absence of TCA at any time point in the growth curve. 
Growth of C difficile in the broths was quantified by taking OD600 measurements using a plate 
spectrometer. Error bars represent the mean ± standard deviation. 
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Figure S12: Schematic of key metabolite interactions with C difficile during health, CDI, and recurrent 
CDI. Initial antibiotic treatment decreases the diversity of the gut microbiota, killing bacteria that 
produce valerate and bile salt hydrolase (an enzyme that degrades TCA). This results in increased levels 
of TCA and decreased levels of valerate, allowing for C difficile spore germination and vegetative growth 
(respectively). Treatment for CDI (vancomycin/metronidazole) decreases C difficile vegetative cells, but C 
difficile spores remain and microbial community diversity remains low. Again, this antibiotic exposure 
results in an environment with high TCA and low valerate, allowing the remaining C difficile spores to 
germinate and grow once vancomycin/metronidazole is stopped. When a patient receives FMT for 
recurrent CDI (usually within 1-2 days of stopping suppressive antibiotics) valerate levels (and valerate 
producing bacteria) and bile salt hydrolase levels (and bile salt hydrolysing bacteria) are restored, 
resulting in an environment that inhibits both C difficile germination and vegetative growth. 
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